Alpha-Linoleic Acid

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart inflammation skin

Research Overview

Across the provided abstracts, alpha-linolenic acid (ALA; often discussed within the broader class of omega-3 polyunsaturated fatty acids, ω-3 PUFAs) is most frequently studied in relation to cardiovascular health, particularly cardiovascular disease (CVD) prevention and vascular function. Reviews emphasize ω-3 PUFAs’ roles in reducing “residual” cardiovascular risk and describe mechanisms extending beyond triglyceride lowering, including pleiotropic vascular effects and modulation of vascular tone relevant to blood pressure regulation. Beyond cardiometabolic outcomes, ALA-related pathways also appear in systems-level studies of inflammatory and neurologic disease (e.g., metabolomics work in multiple sclerosis identifying perturbations in lipid metabolism pathways that include ALA), and in preclinical neurodegeneration research (e.g., ALA investigated for effects on oxidative stress, neuroinflammation, neuronal death, and memory deficits in amyloid-beta models). Additional, more applied research uses α-linoleic/linolenic fatty acids as components in delivery systems (e.g., nanoparticle formulations to improve nutraceutical bioavailability), indicating interest in formulation science rather than direct clinical efficacy of ALA itself.

The strongest evidence base in these abstracts supports a cardiovascular relevance for ω-3 PUFAs overall, with the most consistent clinical trial momentum highlighted for high-dose EPA-only formulations rather than ALA specifically. For blood pressure, the narrative synthesis points to a body of clinical studies and meta-analyses suggesting modest beneficial effects of ω-3 PUFAs in both hypertensive and normotensive individuals, plausibly mediated by endothelial-dependent and -independent mechanisms affecting vascular tone. In contrast, evidence for ALA’s direct therapeutic effects in neurologic conditions is presented primarily as preclinical (animal/cellular) or associative (metabolomic pathway perturbations) rather than definitive clinical benefit, and thus is suggestive but not yet confirmatory.

Key gaps include disentangling ALA-specific effects from those of its long-chain derivatives (EPA/DHA) and from mixed ω-3 interventions, given that clinical outcome benefits are not uniformly replicated across trials and appear formulation- and dose-dependent. More research is needed in well-powered randomized controlled trials that isolate ALA (dose, duration, and background diet), use standardized biomarkers (including conversion to EPA/DHA), and evaluate hard clinical endpoints beyond intermediate risk factors. In neurologic and immune-mediated diseases (e.g., MS, Alzheimer’s-related models, allergic rhinitis–microbiome/metabolome links), the abstracts point to mechanistic and biomarker opportunities, but translation requires longitudinal human studies to validate ALA-related metabolic signatures as diagnostic/prognostic tools and to test whether ALA supplementation meaningfully modifies disease activity, symptoms, or progression.

1. What conditions has Alpha-Linoleic Acid been studied for?

  • Cardiovascular disease (CVD) risk and prevention: ALA is discussed as an omega-3 PUFA precursor within broader omega-3 research on cardiovascular prevention and “residual risk.”

  • Blood pressure / hypertension: Omega-3 PUFAs (including ALA and derivatives EPA/DHA) have been evaluated for effects on blood pressure regulation and vascular tone.

  • Bone health / age-related bone mineral density (BMD) decline: A randomized, double-blind, placebo-controlled trial tested perilla seed oil (rich in α-linolenic acid) for bone outcomes over 12 months.

  • Alzheimer’s disease-related pathology (preclinical): An animal study investigated ALA effects on oxidative stress, neuroinflammation, neuronal death, and memory deficits induced by amyloid-beta.

  • Multiple sclerosis (MS) (biomarker/pathway relevance): Metabolomics studies identify lipid metabolism involving the “alpha-linoleic acid pathway” as commonly perturbed in MS and its preclinical model (this is pathway association, not necessarily supplementation trials).

  • Risk–benefit context in linseed (flaxseed) consumption: A quantitative risk–benefit assessment considered increased ALA intake as part of sensitivity analyses when evaluating health impacts of higher linseed intake.

2. Does it work in treating those conditions? Summarize the evidence.

  • CVD outcomes (clinical evidence is mixed for omega-3s overall; ALA-specific effects not clearly established here): The abstracts note that epidemiological/retrospective studies often suggest omega-3 PUFA intake lowers CVD risk, but “early intervention trials have not consistently confirmed this effect.” More recent large RCTs support benefit particularly for high-dose EPA-only formulations—this strengthens omega-3 evidence generally, but does not directly prove ALA supplementation treats or prevents CVD events.

  • Blood pressure: A narrative review reports that multiple clinical studies and meta-analyses suggest omega-3 PUFAs can help regulate blood pressure in hypertensive and normotensive individuals, likely via vascular/endothelial mechanisms. Another abstract notes fish oil (EPA/DHA) can modestly reduce blood pressure at doses >3 g/day. These findings support omega-3s for BP lowering, but the abstracts do not isolate ALA’s independent effect versus EPA/DHA.

  • Bone health (best direct human evidence in these abstracts): In a 12-month randomized, double-blind, placebo-controlled trial in Japanese adults (n=52), daily perilla oil (7 mL/day; rich in α-linolenic acid) led to increased %YAM (calcaneal ultrasound-derived measure related to bone status) and decreased TRACP-5b (a bone resorption marker) versus placebo, with BALP unchanged. This pattern is consistent with reduced bone resorption rather than increased bone formation.

  • Alzheimer’s disease-related outcomes (preclinical): The abstract describes an animal model study designed to test whether ALA improves Aβ-induced oxidative stress, neuroinflammation, neuronal death, and memory deficits. Because the provided text is truncated before results, efficacy cannot be confirmed from these abstracts alone; at most, it indicates preclinical investigation and rationale.

  • MS: The MS abstract supports that lipid metabolism pathways involving the “alpha-linoleic acid pathway” are perturbed and may yield biomarkers/targets. This is not evidence that ALA supplementation treats MS; it is evidence of pathway involvement and potential diagnostic/therapeutic target discovery.

Bottom line from these abstracts: The strongest direct intervention evidence presented is for bone health using perilla oil (ALA-rich). For CVD and blood pressure, the evidence summarized is broader omega-3 literature with stronger RCT support for EPA-only than for ALA specifically.

3. What health benefits does it have?

  • Potential cardiovascular support as part of omega-3 PUFA intake: Omega-3 PUFAs are described as having vascular-protective “pleiotropic” actions beyond triglyceride lowering and may contribute to reduced incidence of stroke/atherosclerosis and cardiovascular disease in observational research (though intervention trial results have been inconsistent overall).

  • Blood pressure regulation (omega-3 class effect): Clinical studies/meta-analyses summarized in the review suggest omega-3 PUFAs can lower or regulate blood pressure, likely through effects on vascular tone and endothelial function. The abstracts more directly support EPA/DHA (fish oil) at higher doses, but ALA is included within the omega-3 PUFA family discussed.

  • Bone health: In the 12-month RCT, ALA-rich perilla oil improved a bone status measure (%YAM) and reduced a bone resorption marker (TRACP-5b), suggesting a benefit for age-related bone decline via reduced resorption.

  • Oxidative stress balance (indirect evidence): In the perilla oil trial, the BAP/d-ROM ratio increased versus placebo, consistent with an improved antioxidant/oxidative stress profile in that study context.

  • Potential neuroprotective rationale (preclinical): ALA is described as showing neuroprotective outcomes in rat models of ischemic stroke and Parkinson’s disease, and it is being investigated in an amyloid-beta model relevant to Alzheimer’s disease (results not provided in the excerpt).

4. Does it have any downsides or side effects?

  • Evidence gaps for ALA-specific adverse effects in these abstracts: The provided abstracts do not report specific side effects attributable to ALA supplementation itself (e.g., bleeding risk, GI effects), and the perilla oil RCT excerpt does not mention adverse event rates.

  • Food-source risk considerations (linseed/flaxseed context): A quantitative risk–benefit assessment of increasing linseed intake up to 45 g/day evaluated cadmium exposure as a risk and found that fiber-related benefits outweighed cadmium-related harms in all modeled scenarios. ALA was included in sensitivity analysis and increased the estimated benefit. This highlights that some ALA-rich foods may carry contaminant-related risks depending on source and intake level, even if overall modeled net health impact was favorable.

  • Conversion inefficiency to EPA/DHA (a limitation rather than a “side effect”): One abstract notes conversion of precursor fatty acids (including α-linolenic acid) to longer-chain PUFA (EPA/DHA) is inefficient. Practically, this may limit expected benefits if someone relies on ALA to raise EPA/DHA substantially.

Practical limitation: Several cardiovascular/blood pressure benefits in these abstracts are more strongly tied to EPA/DHA (fish oil) than to ALA, so substituting ALA for EPA/DHA may not reproduce the same magnitude of effect.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (e.g., genotype-stratified responses or adverse effects) for alpha-linolenic acid.

  • No direct evidence here linking ALA’s benefits/risks to specific genetic variants.

  • Relevant research gap: Because conversion of ALA to EPA/DHA is described as inefficient, genetic variation in fatty-acid desaturase/elongase pathways could plausibly influence response, but this is not addressed in the supplied abstracts and cannot be concluded from them.

References

  1. Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review.
    Ewa Sokoła-Wysoczańska, Tomasz Wysoczański, Jolanta Wagner, Katarzyna Czyż, Robert Bodkowski, Stanisław Lochyński, Bożena Patkowska-Sokoła (2018) - Nutrients
  2. Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
    Gabriele Brosolo, Andrea Da Porto, Stefano Marcante, Alessandro Picci, Filippo Capilupi, Patrizio Capilupi, Nicole Bertin, Cinzia Vivarelli, Luca Bulfone, Antonio Vacca, Cristiana Catena, Leonardo A Sechi (2023) - International journal of molecular sciences
  3. An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview.
    Insha Zahoor, Bin Rui, Junaid Khan, Indrani Datta, Shailendra Giri (2021) - Cellular and molecular life sciences : CMLS
  4. Discovery of Aryloxy-, Arylthio-, and Arylamino-Containing Acethydrazides as Fungicidal Agents.
    Hongbin Fang, Zhanfang Chen, Yang Liu, Tiancheng Zhang, Jing Chang, Zizheng Li, Lingxiao Zhang, Junkang Sui, Jing Ru, Yucheng Gu, Xuewen Hua (2023) - Journal of agricultural and food chemistry
  5. Punicic Acid and Its Role in the Prevention of Neurological Disorders: A Review.
    Claudia M Guerra-Vázquez, Mariana Martínez-Ávila, Daniel Guajardo-Flores, Marilena Antunes-Ricardo (2022) - Foods (Basel, Switzerland)
  6. Structural characterization and bioavailability of ternary nanoparticles consisting of amylose, α-linoleic acid and β-lactoglobulin complexed with naringin.
    Tao Feng, Ke Wang, Fangfang Liu, Ran Ye, Xiao Zhu, Haining Zhuang, Zhimin Xu (2017) - International journal of biological macromolecules
  7. Protective effect of alpha-linoleic acid on Aβ-induced oxidative stress, neuroinflammation, and memory impairment by alteration of α7 nAChR and NMDAR gene expression in the hippocampus of rats.
    Nahaleh Tofighi, Masoumeh Asle-Rousta, Mehdi Rahnema, Rahim Amini (2021) - Neurotoxicology
  8. Fecal and serum metabolomic signatures and gut microbiota characteristics of allergic rhinitis mice model.
    Zhen Chen, Shancai He, Yihan Wei, Yang Liu, Qingqing Xu, Xing Lin, Chenyu Chen, Wei Lin, Yingge Wang, Li Li, Yuanteng Xu (2023) - Frontiers in cellular and infection microbiology
  9. Perilla seed oil improves bone health by inhibiting bone resorption in healthy Japanese adults: A 12-month, randomized, double-blind, placebo-controlled trial.
    Kentaro Matsuzaki, Shahdat Hossain, Harumi Wakatsuki, Yoko Tanabe, Miho Ohno, Setsushi Kato, Osamu Shido, Michio Hashimoto (2023) - Phytotherapy research : PTR
  10. Biological Activity of Sacha Inchi (
    Denny M Cárdenas, Lyz Jenny Gómez Rave, Javier Andrés Soto (2021) - Food technology and biotechnology
  11. Evaluating the health impact of increased linseed consumption in the Danish population.
    Malene Outzen, Sofie Theresa Thomsen, Rikke Andersen, Lea Sletting Jakobsen, Marianne Uhre Jakobsen, Maarten Nauta, Gitte Ravn-Haren, Jens Jørgen Sloth, Kirsten Pilegaard, Morten Poulsen (2024) - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  12. Embryonic mercury exposure in zebrafish: Alteration of metabolites and gene expression, related to visual and behavioral impairments.
    Noraini Abu Bakar, Wan Norhamidah Wan Ibrahim, Abdul Rahman Zulkiflli, Nur Atikah Saleh Hodin, Tae-Yoon Kim, Yee Soon Ling, Mohd Mokrish Md Ajat, Khozirah Shaari, Shamarina Shohaimi, Nurrul Shaqinah Nasruddin, Siti Munirah Mohd Faudzi, Cheol-Hee Kim (2023) - Ecotoxicology and environmental safety
  13. Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors.
    Mahinda Y Abeywardena, Glen S Patten (2011) - Endocrine, metabolic & immune disorders drug targets
  14. Comparison of Chemical Profiles, Anti-Inflammatory Activity, and UPLC-Q-TOF/MS-Based Metabolomics in Endotoxic Fever Rats between Synthetic Borneol and Natural Borneol.
    Liang Zou, Yan Zhang, Wei Li, Jinming Zhang, Dan Wang, Jia Fu, Ping Wang (2017) - Molecules (Basel, Switzerland)
  15. Decreasing the overall environmental impact of the Dutch diet: how to find healthy and sustainable diets with limited changes.
    Gerard Fh Kramer, Marcelo Tyszler, Pieter Van't Veer, Hans Blonk (2017) - Public health nutrition
  16. Physicochemical evaluation of sheep milk yogurts containing different levels of inulin.
    C F Balthazar, C A Conte Júnior, J Moraes, M P Costa, R S L Raices, R M Franco, A G Cruz, A C O Silva (2016) - Journal of dairy science
  17. Metabolic Trajectories Following Contrasting Prudent and Western Diets from Food Provisions: Identifying Robust Biomarkers of Short-Term Changes in Habitual Diet.
    Nadine Wellington, Meera Shanmuganathan, Russell J de Souza, Michael A Zulyniak, Sandi Azab, Jonathon Bloomfield, Alicia Mell, Ritchie Ly, Dipika Desai, Sonia S Anand, Philip Britz-McKibbin (2019) - Nutrients
  18. Synbiotic-Glyconutrient Additive Reveals a Conducive Effect on Growth Performance, Fatty Acid Profile, Sensory Characteristics, and Texture Profile Analysis in Finishing Pig.
    Vetriselvi Sampath, Jae Hong Park, In Ho Kim (2023) - Foods (Basel, Switzerland)
  19. Effect of a High Linoleic Acid Diet on Pregnant Women and Their Offspring.
    Deepti Nayyar, Joanne M Said, Helen McCarthy, Deanne H Hryciw, Lannie O'Keefe, Andrew J McAinch (2024) - Nutrients
  20. Diet quality and nutrient density in pregnant women according to adherence to Mediterranean diet.
    Sara Castro-Barquero, Marta Larroya, Fátima Crispi, Ramon Estruch, Ayako Nakaki, Cristina Paules, Ana María Ruiz-León, Emilio Sacanella, Tania Freitas, Lina Youssef, Leticia Benitez, Irene Casas, Mariona Genero, Silvia Gomez, Francesc Casanovas-Garriga, Eduard Gratacós, Rosa Casas, Francesca Crovetto (2023) - Frontiers in public health


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!